Portage Biotech (NASDAQ:ALP) CEO Brittany Kaiser Buys 9,350 Shares

Portage Biotech Inc. (NASDAQ:ALP) CEO Brittany Kaiser bought 9,350 shares of the business’s stock in a transaction dated Wednesday, September 9th. The shares were purchased at an average price of $5.35 per share, for a total transaction of $50,022.50. Following the transaction, the chief executive officer directly owned 16,766 shares of the company’s stock, valued at approximately $89,698.10. This represents a 126.08% increase in their position. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink.

Portage Biotech Stock Up 3.0%

Shares of NASDAQ ALP opened at $4.16 on Tuesday. The company has a quick ratio of 0.31, a current ratio of 0.31 and a debt-to-equity ratio of 0.01. Portage Biotech Inc. has a 52-week low of $3.20 and a 52-week high of $690.00. The business has a 50-day moving average price of $10.53 and a 200 day moving average price of $14.74. The stock has a market cap of $6.45 million, a PE ratio of -0.51 and a beta of 0.54.

Portage Biotech (NASDAQ:ALP) last posted its quarterly earnings data on Thursday, July 16th. The company reported $23.75 earnings per share for the quarter. The firm had revenue of $0.05 million during the quarter. Equities research analysts forecast that Portage Biotech Inc. will post -14 earnings per share for the current year.

Analyst Ratings Changes

ALP has been the topic of a number of recent research reports. Wall Street Zen upgraded shares of Portage Biotech to a “hold” rating in a research note on Saturday. HC Wainwright began coverage on Portage Biotech in a report on Monday, August 17th. They set a “neutral” rating and a $12.50 price target on the stock. Zacks Research upgraded Portage Biotech to a “hold” rating in a research report on Tuesday, August 18th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Portage Biotech in a research note on Friday, July 24th. Two investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Portage Biotech presently has an average rating of “Reduce” and an average price target of $12.50.

About Portage Biotech

Portage Biotech (NASDAQ:ATON) is a biotechnology company focused on acquiring, developing and advancing therapeutic candidates and platform technologies. The company concentrates its development efforts primarily in areas such as oncology, immunology/inflammation and infectious disease, seeking to move programs from discovery and preclinical stages into clinical development through subsidiary companies and collaborative arrangements.

Portage structures its operations to support a diversified pipeline, advancing both small molecules and biologics by funding preclinical research, conducting clinical trials, and managing regulatory interactions.